JMP Securities Initiates Coverage On Ambrx Biopharma with Market Outperform Rating, Announces Price Target of $15
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has initiated coverage on Ambrx Biopharma (NASDAQ:AMAM) with a Market Outperform rating and a price target of $15.
September 25, 2023 | 9:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ambrx Biopharma has been given a Market Outperform rating by JMP Securities with a price target of $15.
The initiation of coverage by JMP Securities with a Market Outperform rating and a price target of $15 indicates a positive outlook for Ambrx Biopharma. This could potentially attract more investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100